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A B S T R A C T
Staphylococcus aureus is a frequent colonizer of the upper airways in chronic rhinosinusitis with nasal polyps, but
also resides intramucosally; it has been shown that secreted staphylococcal proteins such as enterotoxins and
serine proteases induce the release of cytokines such as IL-5. We have analyzed nasal polyp tissue freshly ob-
tained during routine surgery, which did or did not contain cultivatable S. aureus, to study spontaneous IL-5
production by nasal polyp tissue over 24 and 72 h in tissue culture. In S. aureus-positive samples we interfered by
killing the bacteria using antibiotics or S. aureus speciﬁc intravenous staphylococcal phages (ISP), active or heat-
inactivated. Phage-neutralizing antibodies were used to demonstrate the speciﬁcity of the phage-mediated ef-
fects. We monitored S. aureus colony forming units, and identiﬁed S. aureus proteins by mass spectrometry. We
demonstrate that cultivatable S. aureusmay be found in type-2 inﬂamed nasal polyps; the pathogen is replicating
within 24 h and secretes proteins, including enterotoxins and serine proteases. The presence of S. aureus was
associated with a signiﬁcantly higher release of IL-5. Killing of S. aureus by antibiotics or speciﬁc ISP sig-
niﬁcantly reduced the IL-5 release. The suppressive activity of the bacteriophage on IL-5 be abolished by heat
inactivation or anti-phage antibodies.
Biological signiﬁcance: In this study, we used high resolution mass spectrometry to identify S. aureus proteins
directly in infected nasal polyp tissue and nasal polyp tissue incubated over 24 and 72 h in culture. We dis-
covered bacterial proteins including enterotoxins and serine proteases like proteins. These experiments indicate
a direct role of S. aureus in the regulation of IL-5 production in nasal polyps and may suggest the involvement of
bacterial proteins detected in the tissues.
1. Introduction
Staphylococcus aureus has been associated with chronic in-
ﬂammatory airway diseases, as the bacteria may colonize the airways
and release proteins such as staphylococcal enterotoxins (SEs) and re-
lated molecules which might severely impact the mouse and human
immune system [1,2]. SE-IgE, speciﬁc IgE antibodies to staphylococcal
enterotoxins (SEs), as a marker of immune contact with S. aureus, have
been associated with asthma throughout Europe [3], and speciﬁcally
severe asthma [4,5], as well as chronic rhinosinusitis with nasal polyps
(CRSwNP; [2,6]). The abundancy of SE-IgE was related to more severe
disease, as manifested by the presence of comorbid asthma and recur-
rence of disease after surgery [6,7]. Recently, Chen et al. [7a] de-
monstrated that SEs could function as an allergen and as a super-
allergen in nasal polyp tissue. The release of high concentrations of
cytokines, including type 2 cytokines such as IL-5, has been observed
upon exposure of mucosal tissue to SEs [8] and serine proteases (spl's)
[18].
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S. aureus has been shown to permanently colonize the nose in about
a third of European adults, but can be found in up to 85% of patients
with chronic rhinosinusitis with nasal polyps [9]. However, no diﬀer-
ence in the ability of production of classical superantigens has been
found between colonizing S. aureus strains obtained from CRSwNP
patients vs. healthy controls [10]. In contrast to healthy mucosal tissue,
however, S. aureus is frequently found intramucosally and in-
tracellularly in CRSwNP tissues [11]; furthermore, macrophages in se-
verely inﬂamed polyp tissues are at least in part alternatively activated
and unable to eﬀectively phagocytize and kill S. aureus, as shown by
Krysko et al. [12], and may allow the pathogen to survive and to secrete
proteins intramucosally. Although we have shown recently that se-
creted proteins from S. aureus can be detected in nasal polyp tissue
[12a], and that both SEs and spl's have the potential to induce the re-
lease of IL-5 upon exposure to human nasal mucosal tissue [8,18], it has
not been demonstrated yet that S. aureus can be cultured from nasal
polyp tissue and is spontaneously producing and releasing proteins “ex-
vivo” into the mucosal tissue of CRSwNP patients, associated with the
release of type-2 inﬂammatory cytokines.
We therefore aimed to use ex vivo human tissue, freshly obtained
from CRSwNP patients during surgery for their disease, to study the
presence of S. aureus, its secretome, and eﬀects of the released proteins
on the mucosal inﬂammation, measured here as spontaneous release of
Interleukin-5 (IL-5). To demonstrate the direct link between the activity
of the germ and cytokine release, we intended to eradicate tissue S.
aureus using both antibiotics and germ-speciﬁc bacteriophages; and to
evaluate the release of secreted staphylococcal proteins into the mu-
cosal tissues by proteomics.
2. Material and methods
2.1. Patients and sample collection
Study subjects were selected on the basis of a documented medical
history of chronic rhinosinusitis with nasal polyps (CRSwNP), a pa-
thological nasal endoscopy conﬁrming bilateral nasal polyps and a
pathological CT-Scan of the sinuses, according to the current European
position paper on sinusitis and nasal polyps [13]. Tissue samples from
the ethmoidal sinuses were collected from patients during endoscopic
sinus surgery procedures, which were indicated for clinical reasons,
independent of this study. Surgery was performed at the Department of
Otorhinolaryngology at Ghent University Hospital, Belgium. The local
Ethics Committee approved the study (B670201112019), and written
informed consent was obtained from all patients prior to surgery.
Clinical data of the patients are summarized in Table 1.
2.2. Tissue culture for identiﬁcation of bacteria
Several nasal polyps from each patient with a diameter of at least
5 mm were washed vigorously in 0.9% NaCl, cut open with a sterile
scalpel to obtain small tissue pieces from the center of the polyp, which
were cultured overnight at 37 °C in Tryptic Soy Broth (TSB). This was
followed by plating 10 μL of the TSB-overnight culture on Columbia
agar with 5% sheep blood as well as on Mannitol Salt Agar (MSA), a
selective growth medium for S. aureus (all media from Becton
Dickinson, Erembodegem, Belgium). After further incubation for 24 h
at 37 °C, bacterial colonies were identiﬁed by MALDI-MS (Bruker
Daltonics, Germany).
For quantifying S. aureus in the tissue culture experiments, deci-
normal serial dilutions from the ex vivo nasal polyp supernatant sam-
ples were prepared and 100 μL of each dilution was inoculated onto
MSA plates. Colonies were counted after incubation for 24 h at 37 °C.
All culture dilutions were done in triplicate. The detection threshold for
S. aureus and Staphylococcus epidermidis in the overnight cultures was
100 CFU/mL.
After overnight culture several colonies were picked, using a 1 μL
disposable loop, and spotted evenly over the wells of the MALDI target
plate. The preparations were covered with 1 μL of matrix solution (sa-
turated solution of α-cyano-4-hydroxycinnamic acid in 50% acetonitrile
and 2.5% triﬂuoroacetic acid) and dried for 2 min at RT. A bacterial test
standard (BTS 255343, Bruker Daltonics, Germany) was used as posi-
tive control for MALDI spectra, and an empty well covered with matrix
served as a negative control. Mass spectra were generated and analyzed
with a Microﬂex Biotyper™ spectrometer (Bruker Daltonics) and Bruker
Daltonics' ﬂexControl version 3.0 software, using the manufacturer's
standard settings [13a].
2.3. Bacteriophages
The LPS-free S. aureus bacteriophage ISP was received from Eliava
IBMV (Tbilisi, Georgia) in 2002 and is currently maintained in the
phage collection of the Laboratory Bacteriology Research Ghent
University, Belgium. For the phage propagation we used the clinical S.
aureus strain ‘13 S44 S9’ isolated from a burn wound at the Burn Wound
Centre (Queen Astrid Military Hospital, Brussels, Belgium) in 2006. The
bacterial strain and the phage were cultured on Select Alternative
Protein Source Luria Bertani media (Becton Dickinson, Erembodegem,
Belgium). The agar overlay method with modiﬁcations as described
earlier [14] was used to obtain a high titer (11 log plaque-forming
units (PFU)/mL) phage lysate. Brieﬂy, 1 mL of phage suspension con-
taining 4 log PFU of ISP was mixed with 3.0 mL of molten (45 °C) Al-
ternative Protein Source Luria Bertani top agar (0.7%) and 0.1 mL of a
host bacterial suspension (end concentration of 8 log CFU/mL). This
mixture was plated onto Petri dishes, ﬁlled with a bottom layer of 1.5%
Alternative Protein Source Luria Bertani agar and incubated at 37 °C for
16–18 h. The top agar layer was scraped oﬀ and centrifuged for 20 min
at 6000 ×g. The supernatant was ﬁltered through a 0.45 μmmembrane
ﬁlter (Sartorius Stedim Biotech, Göttingen, Germany). Phage lysate was
subsequently puriﬁed from endotoxins using a commercially available
kit (Endotrap Blue, Hyglos, Germany) according to the instructions of
manufacturer.
The obtained phage lysate was ultracentrifuged at 25,000 ×g for
1 h at 4 °C and the pellet was resuspended in ten times less volume of a
0.9% NaCl solution. Phage particles were enumerated by the agar
overlay method [14]. Brieﬂy, decinormal serial dilutions (from log(0)
to log(−10)) of the bacteriophage suspension were prepared. One
milliliter of each dilution was mixed with 3.0 mL of molten (45 °C)
0.7% Alternative Protein Source Luria Bertani LB top agar and 0.1 mL
of a host bacterial suspension (end concentration of 8 log CFU/mL) and
plated in triplicate onto 90 mm diameter Petri dishes (Plastiques Gos-
selin, Menen, Belgium), ﬁlled with a bottom layer of 1.5% Alternative
Protein Source Luria Bertani agar and incubated for 18–24 h at 37 °C.
To estimate the original bacteriophage concentration, plates with
100–1000 plaques were counted. Each titration was performed in tri-
plicate and the means were calculated.
Heat inactivation of ISP was performed at 90 °C for 15 min. Anti-ISP
Table 1
Patient's clinical data.
Patient clinical data S. aureus negative
CRSwNP
S. aureus positive CRSwNP
Number of subjects 8 9
Age (y), median
(range)
47 (31–77) 47 (28–81)
Gender (male/female) 4/4 5/4
Atopy 6 6
Asthma 6 5
IgE (kU/l) 350.9 (IQR: 251.4–432.1) 428.5 (IQR: 171.4–571.9)
SE-IgE positive 3 3
IL-5 (pg/mL) 270.9 (IQR: 216.2–956.6) 151.6 (IQR: 61.3–326.0)
ECP (μg/l) 13,365 (IQR:
5918–20,075)
10,846 (IQR: 3461–32,230)
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phage serum (APS) was produced by Eurogentec (Seraing, Belgium).
The optimal volume of APS to inactivate phage lysates in the range of
7–9 log PFU/mL was deﬁned by the neutralization method [15].
2.4. Preparation and treatment of human sinonasal tissue fragments
Tissue fragments were prepared by cutting sinonasal tissue into
fragments of± 0.9 mm3. These tissue fragments were suspended at
concentrations of 0.04 g per mL in tissue culture medium RPMI-1640
(Life Technologies, Ghent, Belgium), which contained 2 mM L-gluta-
mine (Life Technologies) and 0.1% BSA (Sigma-Aldrich, Bornem,
Belgium) and were seeded into a 48-well plate at a volume of 1 mL/
well.
Tissue fragments were incubated for 24 or 72 h in tissue culture
medium in a ﬁnal sample volume of 50 μL. To interfere with bacterial
growth, antibiotics (50 IU/mL penicillin, 50 μg/mL streptomycin (P/S))
or active resp. heat inactivated Phage ISP were added to the wells at
concentrations of 9 log PFU/mL, 8 log PFU/mL or 7 log PFU/mL as in-
dicated. In some cases the phage suspensions were preincubated for
30 min with 5 μL of APS, either non-diluted (APS1) or diluted 1:10 in
tissue culture medium (APS2). Following incubation, tissue fragments
and culture supernatants were collected by centrifugation, immediately
snap frozen and stored at −20 °C/−80 °C for proteomics analysis.
2.5. Tissue homogenates and IgE, SE-IgE, ECP and IL-5 assessment
Snap-frozen tissue specimens were weighed, pulverized by means of
a mechanical Tissue Lyser LT (Qiagen, Hilden, Germany) at 50 oscil-
lations per second for 2 min in prechilled eppendorfs and then sus-
pended in a 10 times volume of 0.9% NaCl solution with Complete
Protease Inhibitor Cocktail (Roche, Mannheim, Germany) as described
before [13b].
Tissue homogenate concentrations of total IgE, speciﬁc IgE to a
mixture of S. aureus enterotoxins (staphylococcal enterotoxins A and C
and toxic shock syndrome toxin 1) and ECP were assayed by using the
UniCAP system (Phadia, Uppsala, Sweden). Concentrations of IL-5 were
assayed with commercially available Luminex Performance Assay Kits
and measured on a Bio-Plex 200 Platform (Bio-Rad Laboratories S.A.-
N.V., Nazareth Eke, Belgium).
2.6. Tissue sample preparation for gel-based and gel-free-MS analysis
Following ex vivo cultivation under diﬀerent conditions as de-
scribed above, three snap-frozen nasal polyp tissue fragments were
transferred to teﬂon vessels – pre-cooled in liquid nitrogen and con-
taining a tungsten carbide bead – and disrupted in a bead mill
(Mikrodismembrator S, B. Braun Biotech International GmbH,
Melsungen, Germany; part of Sartorius AG, Göttingen, Germany) at
2600 rpm for 2 min. Tissue powder was resuspended in phosphate-
buﬀered saline (PBS) and subjected to nine cycles of ultrasonication at
50% power (Sonopuls, BANDELIN electronic GmbH & Co. KG, Berlin,
Germany). After pelleting insoluble material by centrifugation, the
protein concentration of the supernatant was determined using a
Bradford assay (Bio-Rad, Hercules, CA, USA).
2.7. Tryptic digestion and sample preparation for MS analysis (in-gel
digestion)
For gel-based analyses, proteins were separated by SDS-poly-
acrylamide gel electrophoresis using NuPAGE precast gels (Invitrogen/
Life Technologies/Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA).
After staining the NuPAGE precast gels with Coomassie brilliant blue G-
250, the complete protein-containing region of the gel was cut and
divided vertically into 10 pieces. Subsequently, gel pieces were de-
stained and subjected to an in-gel tryptic digestion using a trypsin:-
protein mass ratio of 1:15. Peptides were extracted from the gel pieces
by two cycles of 30 min of ultrasonication, ﬁrst using 0.1% (v/v) acetic
acid in water, second using 50% (v/v) acetonitrile/0.05% (v/v) acetic
acid in water. Peptide eluates were afterwards lyophilized, and re-
suspended in Buﬀer A1 (0.1% (v/v) acetic acid, 2% (v/v) acetonitrile in
water). Finally, tryptic peptides were puriﬁed using ZipTip C18
(Millipore Corp., Billerica, MA, USA).
2.8. Tryptic digestion and sample preparation for MS analysis (gel-free
digestion)
Four μg of protein extract buﬀered by 20 mM ammonium bicarbo-
nate were reduced in the presence of 2.5 mM dithiothreitol (DTT) and
then alkylated using 10 mM 2-iodoacetamide (IAA). Finally, proteins
were digested into peptides by 160 ng sequencing-grade modiﬁed
trypsin (Promega GmbH, Mannheim, Germany) per sample overnight.
The digestion was stopped with acetic acid at a ﬁnal concentration of
1%. Tryptic peptides were puriﬁed using ZipTipμ-C18 pipette tips
(Merck Millipore, Billerica, MA, USA).
2.9. Mass spectrometry
LC-MS/MS analyses of gel-free digests were performed by a reverse
phase peptide separation on a Dionex UltiMate 3000 nano-LC system
(Dionex/Thermo Fisher Scientiﬁc, Idstein, Germany). For MS data
generation a Q Exactive mass spectrometer (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) coupled to a TriVersa NanoMate (Advion, Ltd.,
Harlow, UK) was used as described before [16]. Brieﬂy, peptides were
separated on a 25 cm Acclaim PepMap RSLC analytical column (2 μm
C18 particles, Thermo Scientiﬁc, Waltham, MA, USA) with a linear
gradient ranging from 2 to 25% buﬀer (0.1% (v/v) acetic acid in
acetonitrile) in 120 min at a ﬂow rate of 300 nL/min.
For samples from in-gel digestion a reverse phase separation of
peptides was carry out using a nano UPLC (Acquity UPLC system,
Waters, Milford, MA, USA) system coupled with an Orbitrap Velos mass
spectrometer (Thermo Scientiﬁc, Waltham, MA, USA) as described in
detail by Jehmlich et al. [17].
2.10. Identiﬁcation of proteins
In order to improve the sensitivity of the detection and identiﬁca-
tion of bacterial proteins in the presence of a vast excess of human
proteins, an iterative search proﬁle was applied, focusing initially on
the human and then on the bacterial proteins. First, a search was per-
formed with the UniProt human database, containing 40,460 sequences
and 22,585,166 residues, using a Mascot in-house version 2.3.02.
Trypsin was selected as enzyme without any missed cleavage site and a
mass tolerance of 10 ppm for the precursor ion (including 13C shift)
was applied. For fragment ion search, 0.05 Da for the HCD-MS/MS
spectra and 0.5 for CID-MS/MS spectra were applied and carbamido-
methyl (C) conversion was allowed as ﬁxed modiﬁcation. In the second
search S. aureus speciﬁc peptides were identiﬁed by focusing on
tandem-MS spectra which did not pass the signiﬁcance threshold ﬁlter
(p < 0.05) in the ﬁrst iteration. These spectra were researched against
the MSMSpdbb1.1 Staphylococcus aureus database version 2.0
[MSMSpdbb: providing databases of closely related organisms to im-
prove proteomic characterization of prokaryotic microbes.
Bioinformatics 26 [5], 698–9, 2010]. This database contains 14 S.
aureus strains and 13 plasmids namely Mu3 AP009324, S. aureus
Mu50BA000017, AP003367, S. aureus NCTC 8325CP000253, S. aureus
Newman AP009351, S. aureus RF122 AJ938182, S. aureus
USA300_FRP3757, CP000255, CP000256, CP000257, CP000258, S.
aureus USA300_TCH1516, CP000730, CP000731, CP001544, S. aureus
aureus MRSA252 BX571856, S. aureus aureus MSSA476 BX571857,
BX571858, S. aureus COL CP000046, CP000045, S. aureus JH1
CP000736, CP000737, S. aureus JH9 CP000703, CP000704, S. aureus
ED98 CP001781, CP001782, CP001783, CP001784, S. aureus N315,
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BA000018, AP003139. Identical sequences are merged and strain spe-
ciﬁc ones were added by a speciﬁc enzymatic cleavage rule
(cKcRcJcOnJnO). The resulting S. aureus database contained 4374 se-
quences and 1,923,939 residues. It was searched with the Mascot in-
house version 2.3.02 using the following ﬁlter settings: a minimum
protein length of 50 aa, a minimum for J-peptide length of 7 aa, a
maximum for J-peptide length of 35 aa, a minimum for O-peptide
length of 7 aa and a maximum for O-peptide length of 35 aa was ap-
plied. The non-signiﬁcant option from the Re-search tool was used in
order to resubmit unmatched spectra from the dataset obtained from
the ﬁrst search against human sequences. TrypsinJO/P was selected as
enzyme with 2 missed cleavage sites and a mass tolerance of 10 ppm for
the precursor ion (including 13C shift) was allowed. For fragment
search, 0.05 Da for the HCD-MS/MS fragments and 0.5 for CID-MS/MS
fragments were applied. Carbamidomethyl (C) conversion was allowed
as ﬁxed modiﬁcation. A protein hit was accepted if the signiﬁcance
threshold was less then p < 0.05 which is roughly equal to an ion
score > 14–20. Proteins were further gene ontology-based (GO) cate-
gorized using the program ProteinCenter, version 3.13.10011 (Thermo
Scientiﬁc, Waltham, MA, USA).
2.11. Statistical analysis
The data obtained from the two patients groups (S. aureus negative
vs. S. aureus positive) were compared by a non-parametric Mann-
Whitney test. Data derived from human sinonasal ex vivo tissue frag-
ment assays were compared by means of a Wilcoxon signed-rank test
after achieving signiﬁcance in a Friedman test (paired test for> 2
groups). A cutoﬀ of p < 0.05 was used to establish statistical sig-
niﬁcance. All statistics were performed using SPSS Statistics 22 soft-
ware (IBM, Germany).
3. Results
3.1. Patients and presence of S. aureus
Seventeen consecutive patients undergoing surgery for CRSwNP
provided material for research. From the polyp samples of 9 of the
patients, we could isolate and culture S. aureus from the nasal polyp
tissue. There was no statistically signiﬁcant diﬀerence between the
clinical data of the two groups in terms of age, atopy or comorbid
asthma. Furthermore, the groups did not diﬀer signiﬁcantly in total
serum IgE concentrations, speciﬁc IgE-antibodies to staphylococcal
enterotoxins nor in serum concentrations of eosinophil cationic protein
(ECP) or IL-5 (Table 1). Among the cultivatable germs, S. aureus was the
most frequent, followed by S. epidermidis (Table 2).
3.2. IL-5 release in nasal tissue culture
When tissue fragments were taken into culture, we observed spon-
taneous release of IL-5 in all nasal polyp samples, which was> 3-fold
higher in those nasal polyps containing, S. aureus compared to S. aureus-
negative tissues (Fig. 1).
In S. aureus-positive nasal polyp tissue the spontaneous release of IL-
5 was signiﬁcantly reduced by antibiotics as well as by the
bacteriophage ISP (Fig. 2). 8 log PFU/mL phage ISP was the con-
centration as determined before based on its anti-staphylococcal eﬀect.
The antibiotic treatment reduced spontaneous IL-5 concentrations after
24 and 72 h to the levels seen without S. aureus, whereas the eﬀect of
the ISP phage was less pronounced, but signiﬁcant at 72 h. Heat-in-
activation of the phage or co-incubation with Anti-ISP phage serum
(APS) abolished the eﬀect of the phage. By contrast, antibiotics or ISP
phage treatment did not change IL-5 secretion in S. aureus-negative
tissue cultures.
3.3. Quantiﬁcation of S. aureus after ex vivo nasal tissue culture
At the start of experiments (time point zero) no bacteria could be
detected in any samples at/above the detection threshold level deﬁned
as 2 log CFU/mL (Fig. 3). In cultures of S. aureus-positive tissue frag-
ments, massive growth of S. aureus was noticed over 24 to 72 h (med-
ians 6 and 8 log CFU/mL, respectively). Bacterial growth was sig-
niﬁcantly reduced by antibiotics as well as active phage treatment, but
not when phages had been heat-inactivated or neutralized by pre-in-
cubation with APS. ISP at the concentrations of 9 and 8 log/mL could
completely prevent the growth of S. aureus strains for up to 48 h. After
72 h, average bacterial load was in the range 3.4–4.2 log CFU/mL. With
lower concentrations of phage ISP, 7 log PFU/mL, bacterial growth was
already detectable after 24 h; after 72 h it reached an average of
5.7 log CFU/mL, which was still signiﬁcantly less than the average
8 log CFU/mL observed in the absence of phages.
3.4. Identiﬁcation and classiﬁcation of cytoplasmic and secreted S. aureus
proteins in ex vivo cultured nasal tissue
Three independent nasal tissue fragments (BOF1129, BOF1132 and
BOF1209), obtained freshly or after cultivation as described above,
were homogenized, and protein extracts were subjected to MS analysis
to search for the presence of S. aureus proteins. In total, 1.458 S. aureus-
speciﬁc proteins were identiﬁed despite the presence of a large excess of
human proteins (Supplementary Tables 1–3). This high sensitivity was
achieved by extensive pre-fractionation of the samples (175 gel bands
and 18 gel-free samples) in combination with the speciﬁc iterative
Table 2
Bacterial strains present in nasal polyps (culture).
S. aureus negative
CRSwNP
S. aureus positive
CRSwNP
S. aureus 0/8 9/9
S. epidermidis 3/8 1/9
Escherichia coli 3/8 0/9
Pseudomonas aeruginosa 1/8 0/9
 S. aureus negative versus positive NP tissue
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Fig. 1. Spontaneous IL-5 protein release into the supernatants of human nasal polyp
tissue ex-vivo. Data are presented as bar charts showing the median and the interquartile
range. *p < 0.05 (Mann-Whitney test).
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search strategy (see Materials and Methods), which ﬁrst identiﬁed and
excluded the human proteins from the dataset and then searched the
remaining proﬁles against the MSMSpdbb database which contains S.
aureus proteins selectively. Since we also found additional bacteria in
the PCR analyzes (Table 2), a proteome-speciﬁc analysis was also per-
formed. Taking all data together, we found additional proteins be-
longing to S. epidermidis and E. coli. However, most of the identiﬁca-
tions were characterized by single peptide identiﬁcation and Mowse
scores slightly above the threshold. When comparing the median
Mowse scores it is obvious that human protein identiﬁcations (64) and
S. aureus protein identiﬁcations (68) were clearly higher in median than
E. coli [21] or S. epidermidis [19] (Supplementary Fig. 1a). In terms of
these results we believe that the majority of the reliable and signiﬁcant
identiﬁcations belonging to human and S. aureus but not to E. coli and S.
epidermidis.
With further applied diﬀerent types of classiﬁcation analyses. In
order to perform such analyses in a reliable fashion, we ﬁrst calculated
how many proteins ﬁtting to which subspecies in the S. aureus speciﬁc
MSMSpdbb database. This was done for each nasal polyp sample
(Supplementary Fig. 1b). As a result, roughly 86% of the identiﬁed
proteins from the three S. aureus isolates showed homology to the
subspecies S. aureus JH90 and based on this, we performed a percen-
tagewise comparison on this strain only. In summary, the majority of
the proteins were unannotated (50%) in the category cellular compo-
nents from GO. The annotated proteins showed a nearly identical dis-
tribution in all isolates. Most of the proteins were assigned to cytoplasm
(15%) followed by membrane and intracellular ones (5%). A similar
percentage of about 4% was detected for integral component of
membrane, ribosome or ribonucleoprotein complex. Roughly 1–2% of
the proteins were belong the plasma membrane, extracellular region
and cell wall complex (Supplementary Fig. 1c). If one compares the
biological processes from GO, a similar distribution between the iso-
lates can be seen. Again, the majority of proteins cannot be assigned to
any category. The subsequent dominant group was metabolic processes
followed by oxidation and translation. With about 2% or less followed
the other groups, such regulation, transport or transcription
(Supplementary Fig. 1d).
Due to the particular interest in proteins which can be secreted into
the intramucosal or intracellular space of CRSwNP tissues, we focused
now on proteins containing a signal peptide; 177 such proteins were
detected. We focused our attention on superantigens and Spls A–F be-
cause of their known IL-5-inducing potential in nasal tissue culture
[6,8,18]. Considering the minute numbers of S. aureus in fresh nasal
polyps, only a small number of S. aureus secreted proteins was detect-
able, among them SplF. 72 h post-cultivation without anti-S. aureus
treatment, three superantigens were detected, SEA(P), SEI(Q) and
TSST-1. After treatment with antibiotics, no bacterial toxins or pro-
teases were detectable. In comparison the ISP phage treatment two
superantigen-like proteins could be detected (staphylococcal exotoxin 3
and 7). Neutralization of phages by Anti-ISP Phage Serum (APS) or
heat-inactivation did not inhibit the secretion of toxins or serine pro-
teases. The total number of secreted S. aureus proteins detected in the
tissues was highest following tissue culture without inhibition and
signiﬁcantly reduced by antibiotic and ISP treatment. Inactivation of
the phages restored the number of bacterial proteins that could be
identiﬁed (Fig. 4, Table 3).
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Fig. 2. Eﬀects of antibiotics, Phage ISP, heat-inactivated Phage ISP and APS Phage ISP (all 8 log PFU/mL) on the release of IL-5 protein from human nasal polyp tissue ex-vivo. Data are
presented as bar charts showing the median and interquartile range. *p < 0.05 (Wilcoxon test).
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4. Discussion
We here for the ﬁrst time demonstrate that cultivatable
Staphylococcus aureus can be found in type-2 inﬂamed upper airway
mucosal tissue, freshly harvested nasal polyps. In tissue culture those
bacteria are able to replicate within 24 h, they are metabolically active
and are able to secrete proteins, comprising enterotoxins, exotoxins,
serine proteases as well as other proteins, which were detected and
identiﬁed by a sophisticated mass spectrometry approach. The presence
of S. aureus was associated with a signiﬁcantly higher spontaneous re-
lease of interleukin-5, a key cytokine for activation and survival of
eosinophils, by polyp tissue. Killing of S. aureus by antibiotics as well as
by the S. aureus speciﬁc ISP bacteriophage signiﬁcantly reduced or
abolished the spontaneous IL-5 release. The suppressive activity of the
bacteriophage could be reversed by heat inactivation or co-adminis-
tration of phage-neutralizing antibodies, indicating the speciﬁcity of the
suppression. These experiments unequivocally demonstrate the ability
of S. aureus to induce IL-5 production in nasal polyps. It is very likely
that some of the proteins produced by growing bacteria and detected
here contribute to this up-regulation of type 2 inﬂammation, as in the
past we have shown that enterotoxins [8] and serine protease-like
proteins [18], both detected in the tissues after spontaneous bacterial
growth, are capable of inducing IL-5 release from nasal polyp tissues.
S. aureus colonization has been demonstrated to be frequent and
persisting in eosinophilic nasal polyp disease [9,10,19] and was also
associated with recurrence of disease after surgical interventions, pos-
sibly also related to bioﬁlm formation [20]. We and others have shown
before that S. aureus can be found intra-mucosally and intra-cellularly
in nasal polyp tissues [11,21,22]; S. aureus may reside within the epi-
thelial cells, macrophages and mast cells, as demonstrated by PNA-FISH
[11], and may replicate intra-epithelially, as shown by electron mi-
croscopy [21]. Type-2 biased nasal polyp tissues have been suggested to
have a marked deﬁcit in defense against this bacterial species, as in-
creased numbers of alternatively activated macrophages have been
found in this environment, being incompetent to phagocytose and kill
intracellular S. aureus [12]. The same phenomenon also has been
documented in severe asthma [23].
In a mouse asthma model, we studied the role of bacterial en-
terotoxins such as SEB on nasal and bronchial allergic inﬂammation
[24]. Both nasal and bronchial application of SEB enhanced allergen-
induced eosinophilic inﬂammation, correlating with higher transcrip-
tion of mRNA for IL-5, IL-4, and other cytokines, and also increased
titers of OVA-speciﬁc and total IgE in serum. Classical enterotoxins,
especially staphylococcal enterotoxin B (SEB), have been shown to be
capable of inducing Th1, Th2 and Th17-related cytokine release in
nasal mucosal and polyp tissue fragments (8). SEB stimulation over a
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Fig. 3. Quantiﬁcation of S. aureus strains by culturing method in ex-vivo nasal tissue
experiments. ISP Phage, heat inactivated ISP; APS ISP; Antibiotics-50 IU/mL penicillin,
50 μg/mL streptomycin and untreated. The sample volume was 1 mL, the bacterial de-
tection threshold was 2 log CFU/mL. The chart is a summary of results of nasal tissue
samples obtained from six patients infected with S. aureus. Data are presented as bar
charts showing the median and interquartile range. *p < 0.05 (Wilcoxon test). p-Values
vs. baseline for 24 h: antibiotics 0.018, phage ISP 9 log 0.018, phage ISP 8 log 0.018,
phage ISP 7 log 0.018. p-Values vs. baseline for 72 h: antibiotics 0.017, phage ISP 9 log
0.017, phage ISP 8 log 0.027, phage ISP 7 log 0.044.
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Fig. 4. Numbers of secreted S. aureus proteins identiﬁed from three polyp samples
(BOF1129, BOF1132 and BOF1209). Fresh tissue fragments were analyzed as well as
tissue fragments that had been cultured for 72 h with the following additives: (i) none
(untreated), (ii) penicillin/streptomycin (antibiotics), (iii) ISP phages; (iv) heat in-
activated (HI) phages and (v) ISP phages and anti-phage serum (APS). The nLC-MS/MS
analysis was performed with the Orbitrap Velos or Q Exactive using gel-based and gel-free
approaches.
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period of 24 h induced signiﬁcant increases of IL-4, IL-5, and IL-13,
among other cytokines. We may, therefore, assume that the en-
terotoxins found in of ex-vivo cultures of S. aureus-positive nasal polyp
tissue also contributed to the release of IL-5 in the current experiment.
Recently, screening for bacterial allergens, we identiﬁed staphylococcal
serine protease-like proteins (Spls) eliciting IgE antibody responses in
asthmatic patients [18]. In mice, inhalation of SplD induced lung in-
ﬂammation characterized by Th2 cytokines and eosinophil inﬁltration.
Following stimulation with Spls, peripheral blood T cells elaborated
Th2 cytokines as is typical for allergens. Also, making use of an ex vivo
tissue culture model, the local cytokine response was examined in the
nasal polyp tissue model. As expected, SEB induced signiﬁcant amounts
of IL-5, IL-17 and IFN-γ at a low concentration (0.1 μg/mL); SplD in-
creased IL-5 production to the same extent as SEB at higher con-
centrations, but had only marginal eﬀect on IL-17 and IFN-γ. The cy-
tokine response elicited by SplD in the human airway tissue model is
shifted toward Th2 in comparison to SEB. Hence, Spls, which were also
present in the S. aureus-positive tissue cultures, may also contribute to
the observed up-regulation of IL-5.
The current experiments made use of freshly collected human dis-
eased polyp tissue and the spontaneous cytokine release from the tis-
sues was measured over 72 h, without the addition of any stimuli or
bacteria; this way we were able to approach the real-life situation as
closely as possible. These ﬁndings conﬁrm unequivocally that S. aureus
is present within or at the epithelial surfaces of nasal polyp tissue, as
has been shown earlier, but adds knowledge in that this germ is cul-
turable and replicates fast. Furthermore, we could demonstrate that the
germ secrets proteins (“the secretome”) into tissues, in some of which
we and others have demonstrated their activity on human immune
tissue before. Interestingly, although the spontaneous release of IL-5
was signiﬁcantly higher in S. aureus positive samples after 24 and 72 h
in comparison to S. aureus negative samples, there was no diﬀerence in
baseline mucosal cytokine secretion, of SE-IgE antibodies and total IgE
concentrations in serum nor in the clinical presence of comorbid asthma
(see Table 1). This suggests previous exposure and sensitization to S.
aureus also in patients with S. aureus-negative polyps. The presence of
culturable S. aureus may vary over time, and the same patient's tissues
may be positive at another time point, depending on the number of
germs present at that speciﬁc moment. Bacterial counts at baseline were
below 2 log CFU/mL and increased to 6 log and 8 log CFU/mL within
24 h and 72 h in tissue culture, respectively, when untreated. The
growth properties of S. aureus in nasal polyp tissue may also be inﬂu-
enced by competition with other bacterial species, as Table 2 indicates,
since 7 out of 8 S. aureus-negative tissue samples grew S. epidermidis, E.
coli or P. aeruginosa in culture at the moment of sampling, whereas only
1 out of the 9 S. aureus-positive samples was positive for another species
(i.e. S. epidermidis).
Whereas bacterial growth and IL-5 production remained low over
time in S. aureus negative samples, increased bacterial growth and
increased IL-5 production was observed in S. aureus positive tissue
samples, which could be reduced to baseline values by antibiotic
treatment. As antibiotics may target many bacteria and possess anti-
inﬂammatory activities, we included a highly S. aureus-speciﬁc inter-
vention in addition to antibiotics, and made use of ISP bacteriophages
[14]. Increased bacterial growth and S. aureus induced IL-5 production
were dose-dependently reduced by the speciﬁc bacteriophage treatment
over 24 and 72 h, reaching signiﬁcance at 72 h. The inactivation of the
suppressive phages by heat-inactivation or by antibodies directed
against the phages abolished this eﬀect, underlining the speciﬁcity of
the model. In parallel, the number of bacterial proteins that could be
identiﬁed in S. aureus positive samples increased from 10 at baseline to
over 50 proteins at 24 h without treatment, but was reduced by anti-
biotic and phage treatment (n= 3), indicating the speciﬁc involvement
of S. aureus. Among those proteins were SEA(P), SEI(Q) and TSST1 as
well as the serine protease SplF, members of protein families that have
been demonstrated to induce IL5 in nasal tissues [8,18]. In untreated
fresh nasal polyp tissue samples from our hospital, but unrelated to the
current experiments, the following enterotoxins were detected at least
once using high resolution mass spectrometry: SEB, SEG, SEH, SEO,
SEL, and after cultivation the serine protease-like proteins SplA and
SplF in addition. This underlines the secretory activity of S. aureus in
nasal polyp tissue and underlines its possible role in driving the in-
ﬂammatory process.
Although the evidence for a direct role of S. aureus in the regulation
of IL-5 in patients with upper airway disease is striking, we can only
provide indirect evidence for the involvement of secreted proteins. The
only feasible way to inhibit the interaction between the germ and the
mucosa seems to be the killing of the producing bacteria, the eﬀect of
which we clearly demonstrated here using antibiotics and ISP bacter-
iophages. Speciﬁc inhibition, e.g., by neutralizing antibodies, could be a
way of dissecting the individual roles of various secreted proteins in the
process, which, however, are likely to be highly redundant. Probably,
both the bacteria themselves and their secretion products contribute to
the chronic inﬂammatory process in nasal polyposis.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jprot.2017.12.003.
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Table 3
Number of independently identiﬁed S. aureus proteins in three fresh and treated nasal polyp samples by gel-based Orbitrap VELOS MS (OV) and gel-free Q Exactive MS (QE).
fresh 
nasal 
polyp
TP27 - 72h 
no 
treatment
TP28 - 72 h 
penicillin/streptomycin
TP31 - 72 h 
phages
TP34 - 72 h 
ISP phages 
TP37 - 72 h 
heat-inactivated 
phages
OV QE OV QE OV QE OV QE OV QE OV QE
BOF 1209 52 41 396 544 41 43 56 174 65 319 132 335
BOF1129 44 50 57 193 19 41 161 217 80 307 276 430
BOF 1132 32 47 704 819 35 45 27 39 326 488 524 691
Average 43 46 386 519 32 43 81 143 157 371 311 485
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